How should interchangeable rituximab biosimilars be evaluated beyond cost savings?

Do biosimilars really match the reference in the clinic?

The strongest evidence comes from a Cochrane systematic review of 16 randomized controlled trials involving 4,342 lymphoma patients, which found that rituximab biosimilars were likely similar to the reference in progression-free survival, duration of response, and overall survival, with moderate certainty [2]. For serious adverse events, the risk ratio was 1.03 (95% CI 0.94–1.14), meaning no meaningful difference in harm [2]. This is the highest-quality synthesis available, and it directly addresses the core question of clinical equivalence.

Real-world studies extend this to other diseases. In membranous nephropathy, a retrospective study of 201 patients treated with a rituximab biosimilar reported a 75.12% overall remission rate, with a median time to remission of 6 months, and adverse events in 30.85% of patients—comparable to published outcomes with the innovator [3]. Similarly, a matched study in immune thrombocytopenia (ITP) found that biosimilars achieved a 63.5% response rate at 3 months versus 53.5% for matched controls receiving the reference product (p=0.13), and safety was analogous [5]. These studies, though observational, suggest that the equivalence seen in trials holds in broader patient populations.

Is it safe to switch patients between biosimilars and the reference?

Switching is a common concern, but the evidence here is reassuring. A prospective observational study at an Italian hospital followed 83 patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia, of whom 60% experienced at least one switch between biosimilars or from the reference product [1]. The study found no safety signal associated with switching; adverse events were similar in frequency and seriousness to those reported in the literature [1]. This directly supports the practice of interchangeability in real-world settings.

Another real-world study in pediatric patients with complex diseases (77 patients, 187 infusions) compared a biosimilar (Novex) with the innovator and found overall acceptable safety, with infusion-related reactions in 35.1% and delayed reactions in 37.7% of patients, but no difference between products [4]. The authors identified risk factors like first infusion and diagnosis, which are useful for optimizing care, but the key point is that switching did not introduce new risks [4]. Together, these studies indicate that switching is clinically safe, though they are observational and not randomized.

What about product quality and regulatory oversight?

Biosimilars are not identical to the reference, and quality differences can exist. A National Control Laboratory assessment of three rituximab biosimilars in India found significant variations in impurity profiles (acidic and basic variants, aggregates, fragments) compared with the innovator [6]. However, these differences did not affect biological activity in cell-based potency assays (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and binding), with p-values all >0.10 [6]. This means that while analytical differences exist, they may not translate into clinical differences—but it underscores the need for robust regulatory oversight and ongoing quality monitoring.

The Cochrane review's moderate certainty reflects some imprecision in the evidence, and the authors downgraded certainty mainly due to imprecision [2]. This suggests that while the evidence is strong, it is not perfect, and continued pharmacovigilance is warranted. The real-world studies, though smaller, add confidence by showing similar outcomes across different diseases and populations [1][3][4][5]. In summary, evaluation should include clinical endpoints, switching safety, and quality metrics, not just cost.

About These Sources

This answer is built on 6 peer-reviewed studies — published from 2021 to 2026, 2 from 2024 or later, 2 in Q1 journals — selected as the most relevant from 10 studies that passed quality screening, drawn from 44 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions